Spiers A S, Roberts P D, Marsh G W, Parekh S J, Franklin A J, Galton D A, Szur Z L, Paul E A, Husband P, Wiltshaw E
Br Med J. 1975 Dec 13;4(5997):614-7. doi: 10.1136/bmj.4.5997.614.
Forty-two adults and children with previously untreated acute lymphoblastic leukaemia (ALL) were entered into a programme of chemotherapy in which three combinations, each of four drugs were administered in a predetermined cyclical rotation together with cranial irradiation and intrathecal injections of methotrexate. Forty-one patients (98%) entered remission and no patient developed neuroleukaemia. Relapse of ALL occurred in 10 patients, and three patients died during remission, while eight patients stopped treatment after two and a half years and have remained in remission for two to 26 months. Comparison of remission and survival experience in this mixed group of children and adults with the experience of children treated at Memphis and in the Medical Research Council's UKALL-I trial showed no significant differences. On the other hand, analysis by prognostic factors showed that neither age nor blast cell count at presentation had any adverse effect in patients treated in this study. No relapses occurred in nine patients with blast cell counts greater than 20 x 109/1 at presentation. This regimen is effective treatment for ALL and may be of special value in patients with poor prognoses. The regiment has not as yet proved superior for the treatment of children with ALL who do not have adverse prognostic features.
42名先前未经治疗的急性淋巴细胞白血病(ALL)成人及儿童患者进入了一个化疗方案,该方案中三种由四种药物组成的联合用药按预定的周期轮流使用,同时进行颅脑照射及鞘内注射甲氨蝶呤。41名患者(98%)进入缓解期,且无患者发生中枢神经系统白血病。10名患者出现ALL复发,3名患者在缓解期死亡,8名患者在两年半后停止治疗,缓解期持续2至26个月。将这组儿童和成人混合组的缓解及生存情况与在孟菲斯接受治疗的儿童以及医学研究委员会的英国ALL-I试验中的情况进行比较,未发现显著差异。另一方面,通过预后因素分析表明,在本研究中接受治疗的患者中,年龄及就诊时的原始细胞计数均未产生任何不利影响。就诊时原始细胞计数大于20×10⁹/L的9名患者未出现复发。该方案是ALL的有效治疗方法,可能对预后不良的患者具有特殊价值。该方案尚未被证明对无不良预后特征的ALL儿童患者的治疗更具优势。